<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03587376</url>
  </required_header>
  <id_info>
    <org_study_id>CR108462</org_study_id>
    <secondary_id>54861911ALZ0002</secondary_id>
    <secondary_id>2018-000403-17</secondary_id>
    <nct_id>NCT03587376</nct_id>
  </id_info>
  <brief_title>Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat)</brief_title>
  <official_title>Characterization of T-Cell Response in Subjects Previously Treated With JNJ-54861911 (Atabecestat)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine T-cell mediated inflammatory immune response in
      some participants previously exposed to atabecestat.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an exploratory Phase 0 study in participants who previously participated in studies
      (54861911ALZ2002 [NCT02260674], 54861911ALZ2003 [NCT02569398], or 54861911ALZ2004
      [NCT02406027]) with atabecestat. In this study, participants will only have blood drawn. The
      primary hypotheses for this study is that adverse event of elevated liver enzymes observed in
      some participants is caused by a T-cell dependent inflammatory response. Participants will be
      monitored for adverse events and will be called 1 day after the blood draw to assess for any
      adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 30, 2018</start_date>
  <completion_date type="Actual">August 23, 2018</completion_date>
  <primary_completion_date type="Actual">August 23, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Atabecestat-Specific T-cell Mediated Inflammatory Immune Response</measure>
    <time_frame>Day 1</time_frame>
    <description>Number of Participants with Atabecestat-Specific T-cell Mediated Inflammatory Immune Response (via cluster of differentiation [CD] 4+ T-cells and CD8+ T-cells) will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants T-cell Receptor (TCR) Sequencing</measure>
    <time_frame>Day 1</time_frame>
    <description>Participants TCR sequencing will be performed to determine if any particular TCR repertoire is associated with a risk of developing an elevation in liver enzymes following exposure to atabecestat. Participants T-cell receptor repertoire will be sequenced via TCR sequencing techniques.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Participants with Elevated Liver Enzymes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood samples will be collected on Day 1 from participants previously treated with atabecestat and who had elevated liver enzymes while on atabecestat.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants Without Elevated Liver Enzymes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blood samples will be collected on Day 1 from participants who completed at least 3 months of dosing with atabecestat and who did not have the elevated liver enzymes (adverse event) while on atabecestat.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atabecestat</intervention_name>
    <description>Blood samples will be collected from participants previously treated with atabecestat.</description>
    <arm_group_label>Participants Without Elevated Liver Enzymes</arm_group_label>
    <arm_group_label>Participants with Elevated Liver Enzymes</arm_group_label>
    <other_name>JNJ-54861911</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant who received and discontinued atabecestat in one of the following prior
             trials (54861911ALZ2002, 54861911ALZ2003, or 54861911ALZ2004)

          -  Must sign an informed consent form (ICF) indicating that he or she understands the
             purpose of, and procedures required for, the study and is willing to participate in
             the study

          -  Willing and able to adhere to the prohibitions and restrictions specified for this
             study

        Exclusion Criteria:

          -  Anemic based on the last blood draw in the prior atabecestat trial

          -  Donated more than (&gt;) 450 milliliter (mL) of blood in the past 3 months

          -  Currently participating in an atabecestat study (54861911ALZ2002, 54861911ALZ2003, or
             54861911ALZ2004)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ziekenhuis Hoge Beuken</name>
      <address>
        <city>Hoboken</city>
        <zip>2660</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Fernand Widal</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTC North GmbH &amp; Co. KGim Spectrum am UKE</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Ace</name>
      <address>
        <city>Barcelona</city>
        <zip>08014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesmottagningen, M51</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 4, 2018</study_first_submitted>
  <study_first_submitted_qc>July 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2018</study_first_posted>
  <last_update_submitted>October 3, 2019</last_update_submitted>
  <last_update_submitted_qc>October 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

